Download PDF
Deutsche Zeitschrift für Onkologie 2017; 49(01): 38-42
DOI: 10.1055/s-0043-101110
Praxis – Behandlungsprobleme
© Karl F. Haug Verlag in MVS Medizinverlage Stuttgart GmbH & Co. KG

Wechselwirkungsrisiken mit zielgerichtet wirksamen, oralen Tumortherapeutika – ein Überblick

Hans-Peter Lipp
Further Information

Publication History

Publication Date:
27 April 2017 (online)

    Permissions and Reprints

Zusammenfassung

Die klinisch relevantesten Wechselwirkungen mit zielgerichtet wirksamen, oralen Tumortherapeutika sind neben Nahrungseffekten v. a. in Verbindung mit Komedikationen zu sehen, die den Magen-pH-Wert erhöhen (z. B. Protonenpumpeninhibitoren), zu Komplexen im Gastrointestinaltrakt (z. B. Grüner Tee) oder zu Cytochrom-P450-Inhibitionen oder -Induktionen führen.

Abstract

Besides food effects, the most clinically relevant drug interactions between targeted oral anticancer drugs and comedication are primarily based on gastric acid suppression (e. g. proton pump inhibitors), potential complex formation (e. g. by green tea) as well as Cyp450 inhibition or induction.

Schlüsselwörter

Wechselwirkungen - orale Tumortherapeutika - Nahrungseffekte - Protonenpumpeninhibitoren - Komplexbildungen - Cyp450-Inhibition - Cyp450-Induktion

Key words

drug interactions - oral anticancer drugs - food effects - proton pump inhibitors - complex formation - Cyp450 inhibition - Cyp450 induction
 

  • Literatur

  • 1 Bryant AD, Fletcher GS, Payne TH. Drug interaction alert override rates in the Meaningful Use era: no evidence of progress. Appl Clin Inform 2014; 5: 802-813
    Article in Thieme ConnectPubMedGoogle Scholar
  • 2 Chi KN, Spratlin J, Kollmannsberger C. et al. Food effects on abiraterone pharmacokinetics in healthy subjects and patients with metastatic castration-resistant prostate cancer. J Clin Pharmacol 2015; 55: 1406-1414
    CrossrefPubMedGoogle Scholar
  • 3 Devriese LA, Koch KM, Mergui-Roelvink M. et al. Effects of low-fat and high-fat meals on steady-state pharmacokinetics of lapatinib in patients with advanced solid tumours. Invest New Drugs 2014; 32: 481-488
    CrossrefPubMedGoogle Scholar
  • 4 De Wit D, Guchelaar HJ, Den Hartigh J. et al. Individualized dosing of tyrosine kinase inhibitors: are we there yet?. Drug Discov Today 2015; 20: 18-36
    CrossrefPubMedGoogle Scholar
  • 5 Ge J, Tan BX, Chen Y. et al. Interaction of green tea polyphenol epigallocatechin-3-gallate with sunitinib: potential risk of diminished sunitinib bioavailability. J Mol Med 2011; 89: 595-602
    CrossrefPubMedGoogle Scholar
  • 6 Gibbons JA, de Vries M, Krauwinkel W. et al. Pharmacokinetic drug interaction studies with enzalutamide. Clin Pharmacokinet 2015; 54: 1057-1069
    CrossrefPubMedGoogle Scholar
  • 7 Herbrink M, Nuijen B, Schellens JHM, Beijnen JH. Variability in bioavailability of small molecular tytrosine kinase inhibitors. Cancer Treat Rev 2015; 41: 412-422
    CrossrefPubMedGoogle Scholar
  • 8 Lipp HP. Klinisch-pharmakokinetische und physiko-chemische Interaktionen mit niedermolekularen, zielgerichtet wirksamen Tumortherapeutika. Hintergründe, substanzspezifische Effekte und praktische Empfehlungen. Krankenhauspharmazie 2017; 38: 175-185
    PubMedGoogle Scholar
  • 9 Lipp HP, Miller K. Treatment of metastatic castration-resistant prostate cancer: Drug Interaction potentials of abiraterone acetate and enzalutamide. Urologe A 2016; 55: 766-771
    CrossrefPubMedGoogle Scholar
  • 10 Mächler S, Meid AD, Send A. et al. Vor, zum oder nach dem Essen?. DAZ 2016; 156: 2110-2117
    PubMedGoogle Scholar
  • 11 Nelson V, Ziehr J, Agulnik M. et al. Afatinib: emerging next-generation tyrosine kinase inhibitor for NSCLC. Onco Targets Ther 2013; 6: 135-143
    PubMedGoogle Scholar
  • 12 Outeda MM, Salvador GP, Elberdin PL. et al. Management of everolimus and voriconazole interaction in lung transplant patients. Ther Drug Monit 2016; 38: 305-312
    CrossrefPubMedGoogle Scholar
  • 13 Petit-Jean E, Buclin T, Guidi M. et al. Erlotinib: another candidate for the therapeutic drug monitoring of targeted therapy of cancer? A pharmacokinetic and pharmacodynamic systematic review of literature. Ther Drug Monit 2015; 37: 2-21
    CrossrefPubMedGoogle Scholar
  • 14 Thomas-Schoemann A, Blanchet B, Bardin C. et al. Drug interactions with solid tumour-targeted therapies. Oncol Hematol 2014; 89: 179-196
    PubMedGoogle Scholar
  • 15 Van Leeuwen RWF, Peric R, Hussaarts KGAM. et al. Influence of the acidic beverage cola on the absorption of erotinib in patients with non-small-cell lung cancer. J Clin Oncol 2016; 34: 1309-1314
    CrossrefPubMedGoogle Scholar
  • 16 Wind S, Giessmann T, Jungnik A. et al. Pharmacokinetic drug interactions of afatinib with rifampicin and ritonavir. Clin Drug Investig 2014; 34: 173-182
    CrossrefPubMedGoogle Scholar
  • 17 Yago MR, Frymoyer A, Benet LZ. et al. The use of betaine HCl to enhance dasatinib absorption in healthy volunteers with rabeprazole-induced hypochlorhydria. AAPS J 2014; 16: 1358-1365
    CrossrefPubMedGoogle Scholar